Cargando…

Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution’s Clinical Experience

(1) Background: Esthesioneuroblastoma (ENB) is a rare tumor entity originating from the olfactory neuroepithelium. There is a scarcity of data about different treatment strategies. Intensity modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) are advanced radiation techniques that might...

Descripción completa

Detalles Bibliográficos
Autores principales: Liermann, Jakob, Syed, Mustafa, Held, Thomas, Bernhardt, Denise, Plinkert, Peter, Jungk, Christine, Unterberg, Andreas, Rieken, Stefan, Debus, Jürgen, Herfarth, Klaus, Adeberg, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267306/
https://www.ncbi.nlm.nih.gov/pubmed/30463343
http://dx.doi.org/10.3390/cancers10110457
_version_ 1783376037275500544
author Liermann, Jakob
Syed, Mustafa
Held, Thomas
Bernhardt, Denise
Plinkert, Peter
Jungk, Christine
Unterberg, Andreas
Rieken, Stefan
Debus, Jürgen
Herfarth, Klaus
Adeberg, Sebastian
author_facet Liermann, Jakob
Syed, Mustafa
Held, Thomas
Bernhardt, Denise
Plinkert, Peter
Jungk, Christine
Unterberg, Andreas
Rieken, Stefan
Debus, Jürgen
Herfarth, Klaus
Adeberg, Sebastian
author_sort Liermann, Jakob
collection PubMed
description (1) Background: Esthesioneuroblastoma (ENB) is a rare tumor entity originating from the olfactory neuroepithelium. There is a scarcity of data about different treatment strategies. Intensity modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) are advanced radiation techniques that might improve local tumor control. (2) Methods: This retrospective analysis contained 17 patients with ENB (Kadish stage ≥ C: 88%; n = 15). Four patients had already undergone previous radiotherapy (RT). The treatment consisted of either IMRT (n = 5), CIRT (n = 4) or a combination of both techniques (n = 8). Median follow-up was 29 months. (3) Results: In patients that had not been irradiated before (n = 13), calculated overall survival (OS) and progression free survival (PFS) rates after 48 months were 100% and 81% respectively (Kaplan-Meier estimates). Two of four patients that underwent reirradiation died after RT, presumably due to tumor progression. Besides common toxicities, five patients (30%) showed mostly asymptomatic radiation-induced brain changes, most likely due to a disturbance of the blood-brain barrier. (4) Conclusions: Our results demonstrate that IMRT, CIRT, a combined approach of IMRT and CIRT as well as reirradiation with CIRT seem to be feasible and effective treatment methods in ENB.
format Online
Article
Text
id pubmed-6267306
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62673062018-12-03 Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution’s Clinical Experience Liermann, Jakob Syed, Mustafa Held, Thomas Bernhardt, Denise Plinkert, Peter Jungk, Christine Unterberg, Andreas Rieken, Stefan Debus, Jürgen Herfarth, Klaus Adeberg, Sebastian Cancers (Basel) Article (1) Background: Esthesioneuroblastoma (ENB) is a rare tumor entity originating from the olfactory neuroepithelium. There is a scarcity of data about different treatment strategies. Intensity modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) are advanced radiation techniques that might improve local tumor control. (2) Methods: This retrospective analysis contained 17 patients with ENB (Kadish stage ≥ C: 88%; n = 15). Four patients had already undergone previous radiotherapy (RT). The treatment consisted of either IMRT (n = 5), CIRT (n = 4) or a combination of both techniques (n = 8). Median follow-up was 29 months. (3) Results: In patients that had not been irradiated before (n = 13), calculated overall survival (OS) and progression free survival (PFS) rates after 48 months were 100% and 81% respectively (Kaplan-Meier estimates). Two of four patients that underwent reirradiation died after RT, presumably due to tumor progression. Besides common toxicities, five patients (30%) showed mostly asymptomatic radiation-induced brain changes, most likely due to a disturbance of the blood-brain barrier. (4) Conclusions: Our results demonstrate that IMRT, CIRT, a combined approach of IMRT and CIRT as well as reirradiation with CIRT seem to be feasible and effective treatment methods in ENB. MDPI 2018-11-20 /pmc/articles/PMC6267306/ /pubmed/30463343 http://dx.doi.org/10.3390/cancers10110457 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liermann, Jakob
Syed, Mustafa
Held, Thomas
Bernhardt, Denise
Plinkert, Peter
Jungk, Christine
Unterberg, Andreas
Rieken, Stefan
Debus, Jürgen
Herfarth, Klaus
Adeberg, Sebastian
Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution’s Clinical Experience
title Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution’s Clinical Experience
title_full Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution’s Clinical Experience
title_fullStr Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution’s Clinical Experience
title_full_unstemmed Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution’s Clinical Experience
title_short Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution’s Clinical Experience
title_sort advanced radiation techniques in the treatment of esthesioneuroblastoma: a 7-year single-institution’s clinical experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267306/
https://www.ncbi.nlm.nih.gov/pubmed/30463343
http://dx.doi.org/10.3390/cancers10110457
work_keys_str_mv AT liermannjakob advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT syedmustafa advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT heldthomas advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT bernhardtdenise advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT plinkertpeter advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT jungkchristine advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT unterbergandreas advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT riekenstefan advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT debusjurgen advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT herfarthklaus advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience
AT adebergsebastian advancedradiationtechniquesinthetreatmentofesthesioneuroblastomaa7yearsingleinstitutionsclinicalexperience